Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

To analyse whether Raltegravir based ART regimen is safe and effective in HIV + Liver transplant recipients.

Trial Profile

To analyse whether Raltegravir based ART regimen is safe and effective in HIV + Liver transplant recipients.

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Apr 2018

At a glance

  • Drugs Efavirenz (Primary) ; Raltegravir (Primary)
  • Indications HIV-1 infections
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 23 Apr 2018 New trial record
    • 07 Mar 2018 Results (n=246 for safety analysis, n=211 for efficacy analysis) presented at the 25th Conference on Retroviruses and Opportunistic Infections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top